|
Helga
Long is a Managing Partner of CTPartners, the premier-quality executive
search firm committed to performance, quality and results. She provides senior
executive search services to corporations in the pharmaceutical, biotechnology,
and medical device business sectors. In another in a series of conversations
about US Healthcare reform and its implications, we take a look at the volatile
Pharmaceutical and biotech sectors. |
Highlights
0:00 This sector is estimated to be a trillion
dollar industry by 2013. At the same time, there is a slowdown, offset only by
the growth of the international marketplace.
1:33 There
are 3 factors in the slowdown: Patent expirations, a reduced pipeline for new
blockbuster drugs and the pressures on pricing from payers, whether that's
individuals or government agencies.
4:27 One of the
bright spots in this sector will be "intervention" strategies like vaccines for
flu, meningitis and even oncology.
5:05 On a strategic
level, companies have been focusing on mergers and consolidation to reduce
costs and redundancies. Others are breaking monolithic companies into more
nimble business units.
6:18 Leaders of these companies
will have to create a new environment of innovation. The future is bright for
those with science skills as well as the "people skills".
7:22 This sector is so unique that, unlike other
industries, bringing outsiders from other industries in will probably not work.
This will mean a great opportunity for those with the academic or industry
background who can commercialize their strategies.